177lu-psma-617
novartis
[' vision', 'crpc', 'prostate']
#asco22 in the vision phase 3 trial, higher whole body mean suv in psma+ mcrpc #prostatecancer strongly correlated with improved pfs and os on treatment with lupsma 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/qcdl195o3E